PD-1/PD-L1 checkpoint blockade in immune-antitumortherapy：advances and perspectives

作     者：Yu LI Ji JIANG Bei HU 

作者机构：Peking Union Medical College Hospital Beijing 100032 China 

出 版 物：《中国药理学与毒理学杂志》 (Chinese Journal of Pharmacology and Toxicology)

年 卷 期：2017年第31卷第10期

页      面：963-963页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：PD-1 PD-L1 checkpoint blockade immuno-therapy research advaces 

摘      要：During the past three decades,studies have shown that tumor cells couldmanipulatehost immunity to escape the immune defenses in the tumor *** of the most important underlying mechanisms is immune-suppression regulated by programmed cell death-1 or its ligand 1(PD-1/PD-L1),which makes PD-1/PD-L1 blockadea promising target of cancer *** could suppress immuno-response of T cells by activating PD-1/PD-L1 signaling ***,inhibiting the interaction between PD-1 and PD-L1 could reconstitute the enduring antitumor immunity in the tumor microenvironment via enhancing the T-cell response,there after augmenting the endogenous antitumor force of the immune *** these lines,inhibitors of PD-1/PD-L1 has been applied in multiple clinical trials against various types of *** studies indicated that PD-1/PD-L1 blockade have demonstrated high efficacy and safety against melanoma,lung,kidney and several other solid tumors,as well as hematological ***,the efficacy of this checkpoint blockade approach is not *** investigation suggested that lack of responses to anti-PD-1/PD-L1 therapy of patients without PD-1/PD-L1 over-expression was *** this review,we summarize the history and current understanding of multiple intrinsic and extrinsic mechanisms via which PD-1/PD-L1 is regulated and research advances in preclinical/clinical aspects of PD-1/PD-L1,as well as significance and perspectives regarding the PD-1/PD-L1 blockade in immune-antitumor therapy.